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Abstract: Stroke is the second leading cause of death worldwide. Ischemia is the most common cause of it which is 
being treated by combined therapy. One important management of acute stroke candidate for recanalization (r-TPA) 
that can perform for some patient with special condition in 3 to 4/5hours of onset in a few centers in Iran. there are 
many studies with different results regard to anti-coagulant therapy in acute stroke. The aim of this study was 
determination of heparin effects on mobility problems among non-hemorrhagic stroke patients. In regard of absence 
of diagnostic tools & teams of acute ischemic stroke treatments  with r-TPA. 
In a double-blind randomized controlled clinical trial, 60 non-hemorrhagic stroke patients in Kashani Hospital in 
Shahrekord were randomly assigned in according to scale definition of NIHSS(part 5 & 6 : motor arms & legs) into 
two groups with same motor signs(0=no drift – 1=drift – 2 = cant’s  resist gravity-3 =no efforts against gravity- 4 = 
no movement UN=untestable): experiment and control groups. While experiment group were subcutaneous received 
5000 to 10000 unit  BID every day for 3 days +aspirin 100-325 mg, control group were received only 100-325 mg 
aspirin. Muscular power and dyspnea &pulses of peripheral veins for evaluation of lung emboli & DVT and 
radiological data in CT( the first and third days) were evaluated after 3 days      in two groups.  
There was no statistically significant difference between two groups in age, gender, power of all limbs, and duration 
of hospitalization. There was no significant difference between two groups in muscular power of upper and lower 
limbs in first day, but it was significant in the third day. In comparison of the muscular power of limbs of patients 
less than 55 years between two groups, there was no significant difference in the first day; however, it was 
significant in the third day. For patients more than 55, the significant difference was seen only in the third day in the 
power of left side limbs.     
This study recommends using heparin in non-hemorrhagic stroke patients which is more efficient than using only 
aspirin. 
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1. Introduction 
Cerebrovascular accident (CVA) or stroke is 
a syndrome which is identified by acute onset of 
neurologic disorders and is prolonged at least 24 
hours, and it is a reflection of local involving of 
central nervous system (Giele et al., 2004; David et 
al., 2002). Stroke is the third leading cause of death 
among worldwide and one of the most important 
neurologic disabling disorders which increases with 
age, with higher mortality among elderly, and higher 
prevalence in men than women (Cecil et al., 2000).     
Heparin and low molecular weight heparin 
(LMWH) are using for treatment of acute stroke 
(Giele et al., 2004). unfractionated heparin (UFH) 
with molecular weight of 3000-30000 dalton and 
mean of 15000 dalton used in the treatment of 
thrombosis with different results , but also has a 
probability of bleeding risk (Hirsh et al., 2001; White 
and Ginsberg, 2003).  
   Due to severe and irreversible 
complications of stroke, the patients have not only 
motion-verbal problems, but also various mental 
complications, as well as economic costs. The aim of 
this study was to evaluate treatment effects of heparin 
on muscular power disorders of acute non-ischemic 
stroke patients. 
 
2. Material and Methods  
In a clinical trial, 60 non-hemorrhagic stroke 
patients, with confirmed nonhemorrhagic stroke 
diagnosed by computed tomography scan (CT- scan) 
or magnetic resonance imaging (MRI), in Kashani 
Hospital in Shahrekord were randomly assigned into 
two groups: experiment and control groups in 2011. 
While experiment group were subcutaneus received 
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5000 -10000 BID units heparin every day for 3 days 
with aspirin, control group were received only 100-
325 mg aspirin. Muscular power, deep veins 
thrombosis and lung emboli were evaluated after 3 
days &CT-scan repeated in two groups. Prothrombin 
time (PT) and partial thromboplastin time (PTT)  and 
INR of all patients were checked every day. 
Exclusion criteria were patients with hemorrhagic 
ischemic stroke, trauma, secondary neurologic 
complications, metabolic disorders (hypokalemia, 
hyponatremia …). Both groups have received one 
gram antacid aluminum hydroxide syrup. Both 
groups were re-CT scanned after 3 days and were 
compared on clinical issues. Muscular powers of 
patients were evaluated. In according to scale 
definition of NIHSS (part 5 & 6 : motor arms & legs) 
into two groups with same motor signs(0=no drift – 
1=drift – 2 = cant;s  resist gravity-3 =no efforts 
against gravity- 4 = no movement UN=untestable): 
experiment and control groups.  Data were obtained 
by questionnaire and results of CT-scan. Chi-square 
and t-students test were used in SPSS (version 17) 
software. 
 
3. Results  
 Table 1 compares muscular power of upper 
and lower limbs in two groups in first day of study. 
Demographic characteristics of both groups on age, 
gender and muscular power did not show any 
significant difference (P>0.05). Muscular power 
mean of both right and left upper and lower limbs 
were statistically significant between two groups 
(P<0.05).  
As the results shows, among control group, CT-scan 
results in the third day were normal in 76.6% of the 
patients (see Table 2). Chronic small vessel and 
middle cerebral artery (MCA) have been observed in 
16.6% and 6.6% of control group patients 
respectively. Among experiment group, CT-scan was 
normal in 40%, 30% had involvement of chronic 
small vessels, and MCA were observed in 20% of 
patients. Lacunar infarction and posterior cerebral 
artery (PCA) were also observed in 6.6% and 3.3% 
respectively. 
 
Table 1- Comparison of muscular power of upper and lower limbs in the first day 
Muscular power Group Mean ± S.D.* P-value 
Right upper limbs Experiment 3.60 ± 1.56 0.16 
Control 3.03 ± 1.56 
Right lower limbs Experiment 3.60 ± 1.58 0.21 
Control 3.07 ± 1.68 
Left upper limbs Experiment 2.87 ± 1.69 0.55 
Control 2.60 ± 1.75 
Left lower limbs Experiment 3.07 ± 1.72 0.67 
Control 2.87 ± 1.90 
*. S.D. = Standard Deviation 
    
Table 2- Comparison of muscular power of upper and lower limbs in the third day between two groups 
Muscular power Group Mean ± S.D.* P-value 
Right upper limbs control 3.93 ± 1.28 0.003 
experimental 4.73 ± 0.64 
Right lower limbs control 3.97 ± 1.29 0.01 
experimental 4.67 ± 0.71 
Left upper limbs control 3.13 ± 1.61 0.001 
experimental 4.47 ± 1.10 
Left lower limbs control 3.33 ± 1.66 0.01 
experimental 4.27 ± 1.28 
    
*. S.D. = Standard Deviation 
  
At the end of third day, mean muscular power was 
increased compared to the first day in two groups 
(Tables 3 and 4). The difference among groups was 
statistically significant (P<0.05). At the end of study, 
the association between muscular power and age 
were evaluated in two groups. While patients with 
age less than 55 in experiment group showed 
increased muscular power of all limbs in the third day 
compared to control group (P<0.05), the muscular 
power in the third day in experiment group was 
increased only in upper left limb (P>0.05). 
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Table 3- Comparison of muscular power of limbs in the first and third days in control group 
Muscular power Control Group Mean ± S.D.* P-value 
Right upper limbs first day 3.60 ± 1.56 0.005 
Third day 3.93 ± 1.28 
Right lower limbs first day 3.60 ± 1.58 0.003 
Third day 3.97 ± 1.29 
Left upper limbs first day 2.87 ± 1.69 0.003 
Third day 3.13 ± 1.61 
Left lower limbs first day 3.07 ± 1.72 0.003 
Third day 3.33 ± 1.66 
*. S.D. = Standard Deviation 
 
 
 
Table 4- Comparison of muscular power of limbs in first and third days in experiment group 
Muscular power Group Mean ± S.D.* P-value 
Right upper limbs first day 3.03 ± 1.56 0.001 
Third day 4.73 ± 0.64 
Right lower limbs first day 3.07 ± 1.68 0.001 
Third day 4.67 ± 0.71 
Left upper limbs first day 2.60 ± 1.75 0.001 
Third day 4.47 ± 1.10 
Left lower limbs first day 2.87 ± 1.90 0.001 
Third day 4.27 ± 1.28 
*. S.D. = Standard Deviation 
 
4. Discussions  
There was a statistically significant variation 
in muscular power of limbs in experiment and control 
groups in our study. We found that simultaneously 
consumption of heparin with other antithrombotic 
drugs such as aspirin is more efficient in 
improvement of motion complications of patients 
with non hemorrhagic ischemic stroke. 
 Lip et al reported the decreasing rates of 
mortality, recurrence, complications, and motion 
disability in patients with consumption of 5000 unit 
heparin twice a day (Lip et al., 2002). If heparin and 
aspirin prescribe at the same time, this effect will 
increase. Our study confirmed this finding; i.e., 
simultaneous consumption of aspirin and heparin 
compounds (LMWH) is more efficient than 
consumption aspirin alone on the motion 
complications of non hemorrhagic ischemic stroke. 
Berge et al in a clinical trial showed that there is no 
evidence for preferring LMWH than aspirin in the 
treatment of atrial fibrillation (AF) patients (Berge et 
al., 2000). Our results are not consistent with their 
results due to potential consumption of aspirin and 
heparin in experiment group and their related 
mechanism of revascularization. Coull et al reported 
that aspirin can improve disability and motion 
problems of ischemic stroke patients (Coull et al., 
2002).                 
 Our study showed that age is an important 
factor in the recovery after stroke, especially in 
patients less than 55. This finding is consistent with 
the findings of Moonis et al that confirmed the 
positive effect of younger age on better prognosis 
(Moonis and Fisher, 2002).  The comparison of 
LMWH and unfractionated heparin in acute 
thromboembolism carried out by Chen et al in 2005 
showed no difference between the effect of these two 
heparins (Chen et al., 2005).  
 No one in our study showed hemorrhagic 
complications or mortality which is consistent with 
the results of Schmulling study (Schmulling et al., 
2003). Strand found that the dilution of blood can 
have positive effect on the decreasing of 
complications (Strand et al., 1984). The study of 
Haley showed that the effect of heparin in the 
treatment of stroke still needs more attention (Haley 
et al., 1988). In another study, it has been confirmed 
that heparin can decline the risk of thromboembolism 
in acute ischemic patients, but not in intracranial 
bleeding and declining of disability (Williamson and 
Street, 2003).   
 
Conclusion: 
 It can be resulted from our findings that 
despite the effectiveness of aspirin in the 
improvement of muscular power among ischemic 
stroke patients, the effect of heparin is more than 
aspirin. The effect is more efficient in younger 
patients than the others. Further  large studies are 
necessary to confirm the effects of heparin and  
bleeding complications. 
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